Would you use a PARP inhibitor as treatment for recurrent platinum-sensitive ovarian cancer with a RAD51 (or other moderate-penetration HRD germline) mutation?
Would your recommendation change if the patient was platinum-resistant?
Community PollStarted
Do you treat patients with moderate-penetrance HRD germline mutations (such as RAD51) with PARP inhibitors in the recurrent, platinum-sensitive setting?
3 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Gynecologic Oncology · VA Boston Healthcare System
Answered on
Of course
Join for free or sign in to see the full answer